Affymetrix Sees 'Opportunity' for Diagnostics Business in Increased FDA Oversight of LDTs | GenomeWeb

By Justin Petrone

Affymetrix believes it stands to benefit from increased US Food and Drug Administration regulation of laboratory-developed tests because several assays that run on its FDA-approved platform have received clearance in the past — a fact that may give it an edge, or at least a head start, in a more regulated molecular-diagnostics environment.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.